

Frederik Persson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/594689/frederik-persson-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

6,898
citations

37
h-index

82
g-index

148
ext. papers

8,684
ext. citations

6.9
avg, IF

5.69
L-index

#	Paper	IF	Citations
136	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 799915	5.6	0
135	Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes? A Review of Intervention Studies. <i>Nutrients</i> , 2022 , 14, 2299	6.7	
134	Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study. <i>Diabetes Care</i> , 2022 , 45, e105-e106	14.6	2
133	What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. <i>Advances in Chronic Kidney Disease</i> , 2021 , 28, 290-297	4.7	
132	Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2021 , 70, 39-50	0.9	5
131	Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 837-846	18.1	17
130	Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. <i>Diabetic Medicine</i> , 2021 , 38, e14405	3.5	0
129	Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies. <i>Kidney International</i> , 2021 , 99, 768-770	9.9	3
128	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2021 , 9, 716	3.2	1
127	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021 , 11, 10624	4.9	3
126	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021 , 44, 1894-1897	14.6	11
125	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. <i>PLoS ONE</i> , 2021 , 16, e0254859	3.7	1
124	A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2354-2363	6.7	0
123	Drug-drug interaction between warfarin and statins: A Danish cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 694-699	3.8	8
122	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 530-539	6.7	4
121	The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. <i>Diabetologia</i> , 2021 , 64, 42-55	10.3	11
120	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. <i>Diabetic Medicine</i> , 2021 , 38, e14459	3.5	1

119	Achieving a useful and person-centred diabetes consultation is a shared responsibility between diabetologists and people with diabetes: a qualitative study of perspectives from people with type 1 diabetes. <i>Diabetic Medicine</i> , 2021 , 38, e14382	3.5	3
118	Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015. <i>Primary Care Diabetes</i> , 2021 , 15, 262-268	2.4	2
117	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021 , 44, 1020-1026	14.6	7
116	Improving frequency of urinary albumin testing in type 2 diabetes in primary care - An analysis of cross-sectional studies in Denmark. <i>Primary Care Diabetes</i> , 2021 , 15, 1007-1011	2.4	2
115	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 901-907	14.6	5
114	Oral treatment of glucocorticoid-induced diabetes mellitus: A systematic review. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13529	2.9	2
113	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. <i>Journal of Nephrology</i> , 2020 , 33, 931-948	4.8	4
112	Study rationale and design of the EANITATE study (EmpAgliFlozin compared to NPH Insulin for sTerold diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment. <i>BMC Endocrine Disorders</i> , 2020 , 20, 86	3.3	3
111	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2077-2088	6.7	3
110	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 301-312	18.1	75
109	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107590	3.2	6
108	Lipoprotein(a) and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107593	3.2	2
107	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. <i>PLoS ONE</i> , 2020 , 15, e0243737	3.7	7
106	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	2
105	Mitigating risk of aldosterone in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 145-151	3.5	12
104	Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. <i>European Heart Journal</i> , 2020 , 41, 328	9.5	10
103	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1700-1711	4.3	52
102	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020 , 41, 255-323	9.5	1360

101	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
100	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
99	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
98	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
97	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
96	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
95	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
94	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
93	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1261-1265	6.7	7
92	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	37
91	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1112-1119	14.6	19
90	Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin. <i>Kidney International</i> , 2019 , 95, 1287-1288	9.9	0
89	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1921-1929	14.6	21
88	Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria. <i>Diabetes Care</i> , 2019 , 42, 1886-1894	14.6	51
87	Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives. <i>Proteomics - Clinical Applications</i> , 2019 , 13, e1800176	3.1	13
86	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 659-666	4.3	7
85	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 296-303	4.3	22
84	Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 470-473	3.2	6

83	YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology. <i>Kidney International</i> , 2018 , 93, 21-22	9.9	3
82	Diagnosis of diabetic kidney disease: state of the art and future perspective. <i>Kidney International Supplements</i> , 2018 , 8, 2-7	6.3	117
81	The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial. <i>Diabetic Medicine</i> , 2018 , 35, 392-393	3.5	3
80	Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. <i>Nephrologie Et Therapeutique</i> , 2018 , 14 Suppl 1, S31-S37	0.6	24
79	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study. <i>PLoS ONE</i> , 2018 , 13, e0196634	3.7	23
78	Interpretation of HbA in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database. <i>Diabetic Medicine</i> , 2018 , 35, 1700-1706	3.5	11
77	N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2899-2904	6.7	7
76	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. <i>Acta Diabetologica</i> , 2018 , 55, 1143-1150	3.9	15
75	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 344-351	6.7	124
74	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 1133-1140	3.2	4
73	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. <i>Endocrinology, Diabetes and Metabolism</i> , 2018 , 1, e00036	2.7	18
72	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018 , 35, 1375-1382	3.5	19
71	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. <i>Diabetes Care</i> , 2017 , 40, e32-e33	14.6	2
70	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 901-905	6.7	31
69	Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014. <i>Diabetes Care</i> , 2017 , 40, e57-e58	14.6	24
68	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney International</i> , 2017 , 91, 982-988	9.9	51
67	Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). <i>BMJ Open</i> , 2017 , 7, e013802	3	11
66	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017 , 18, 52	2.7	23

65	Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 751-759	6.9	89
64	Variability in response to albuminuria-lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1197-1204	3.8	14
63	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1804-1813	6.9	7
62	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017 , 16, 88	8.7	27
61	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1164-1168	3.2	4
60	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2017 , 92, 1242-1248	9.0	17
59	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 709-717	18.1	208
58	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2017 , 60, 1883-1891	10.3	14
57	Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes - A comparative study of two markers to identify high risk patients. <i>Redox Biology</i> , 2017 , 13, 363-369	11.3	14
56	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 239-247	6.7	55
55	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 162-168	3.2	10
54	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1866-1873	4.3	47
53	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 2079-2089	4.3	44
52	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1440-1442	3.2	7
51	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 309-17	18.1	31
50	Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 169-77	6.7	44
49	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016 , 6, e010310	3	92
48	Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e009134	3	9

47	Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2016 , 17,	3	33
46	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 670-4	3.2	47
45	Effects of RAS inhibitors on diabetic retinopathy. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 315-6	18.1	2
44	Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 410-6	6.9	19
43	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015 , 32, 343-52	3.5	49
42	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1146-51	3.2	9
41	Nordic Longitudinal Data from Electronic Medical Records and Full Population National Registers: Unique Opportunities for New Insights in Benefit of Diabetes Patients. <i>Value in Health</i> , 2015 , 18, A726	3.3	5
40	Improving the effectiveness of short-term courses for multidisciplinary health care professionals. <i>Practical Diabetes</i> , 2015 , 32, 180-185	0.7	6
39	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1999-2010	12.7	164
38	Microalbuminuria: a parameter that has changed diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2015 , 107, 1-8	7.4	58
37	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1563-70	4.3	94
36	Sequential RAAS blockade: is it worth the risk?. <i>Advances in Chronic Kidney Disease</i> , 2014 , 21, 159-65	4.7	8
35	Tissue Renin-Angiotensin systems: a unifying hypothesis of metabolic disease. <i>Frontiers in Endocrinology</i> , 2014 , 5, 23	5.7	48
34	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 434-41	3.9	18
33	Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 715-21	14.6	78
32	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013 , 12, 122	8.7	22
31	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013 , 13, 2967-75	4.8	17
30	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013 , 56, 259-67	10.3	117

29	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013 , 14, 161-6	3	18
28	Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?. <i>Journal of Hypertension</i> , 2013 , 31, 1646-52	1.9	23
27	Direct renin inhibition in chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 580-6	3.8	8
26	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 1027-36	4.6	131
25	Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. <i>Diabetic Medicine</i> , 2012 , 29, e184-90	3.5	61
24	Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 686-93	2.3	2
23	Urinary proteomics for early diagnosis in diabetic nephropathy. <i>Diabetes</i> , 2012 , 61, 3304-13	0.9	191
22	Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>New England Journal of Medicine</i> , 2012 , 367, 2204-13	59.2	893
21	Ambulatory tonometric blood pressure measurements in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 453-6	8.1	21
20	High YKL-40 levels predict mortality in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012 , 96, 84-9	7.4	35
19	Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 250-3	3	2
18	Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 118-21	3	19
17	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 387-93	3	45
16	Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2772-7	4.3	5
15	Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. <i>Diabetes Care</i> , 2011 , 34, 2078-83	14.6	48
14	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3242-9	4.3	22
13	Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. <i>Diabetes Care</i> , 2011 , 34, 1192-8	14.6	8
12	Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1025-31	6.9	46

11	Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. <i>Diabetes Care</i> , 2010 , 33, 2304-9	14.6	49
10	Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. <i>Diabetologia</i> , 2010 , 53, 1576-80	10.3	26
9	Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. <i>Diabetes Care</i> , 2009 , 32, 1873-9	14.6	124
8	YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. <i>Diabetes Care</i> , 2009 , 32, 323-8	14.6	107
7	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. <i>Diabetologia</i> , 2009 , 52, 46-9	10.3	24
6	Aliskiren combined with losartan in type 2 diabetes and nephropathy. <i>New England Journal of Medicine</i> , 2008 , 358, 2433-46	59.2	882
5	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. <i>Kidney International</i> , 2008 , 73, 1419-25	9.9	102
4	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008 , 68, 731-8	2	66
3	Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. <i>Diabetes</i> , 2006 , 55, 3550-5	0.9	66
2	Development and validation of a brief, descriptive Danish pain questionnaire (BDDPQ). <i>Acta Anaesthesiologica Scandinavica</i> , 2004 , 48, 486-90	1.9	21
1	Postural stability after inguinal herniorrhaphy under local infiltration anaesthesia. <i>The European Journal of Surgery</i> , 2001 , 167, 449-52		6